Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 12, 2024

BUY
$26.12 - $34.07 $227,008 - $296,102
8,691 New
8,691 $296,000
Q3 2023

Oct 13, 2023

BUY
$21.33 - $59.42 $428,434 - $1.19 Million
20,086 Added 1041.26%
22,015 $504,000
Q2 2023

Jul 10, 2023

BUY
$34.33 - $62.11 $66,222 - $119,810
1,929 New
1,929 $111,000
Q4 2022

Feb 02, 2023

BUY
$24.14 - $30.37 $459,215 - $577,728
19,023 New
19,023 $509,000
Q2 2022

Jul 29, 2022

SELL
$19.74 - $43.01 $82,296 - $179,308
-4,169 Reduced 15.51%
22,714 $493,000
Q1 2022

Apr 29, 2022

SELL
$36.25 - $52.02 $86,420 - $124,015
-2,384 Reduced 8.15%
26,883 $1.08 Million
Q4 2021

Feb 07, 2022

SELL
$43.27 - $65.72 $508,292 - $772,012
-11,747 Reduced 28.64%
29,267 $1.39 Million
Q3 2021

Nov 01, 2021

BUY
$53.61 - $67.5 $2.2 Million - $2.77 Million
41,014 New
41,014 $2.32 Million
Q2 2021

Aug 12, 2021

SELL
$45.13 - $64.99 $1.81 Million - $2.61 Million
-40,199 Closed
0 $0
Q1 2021

May 13, 2021

BUY
$29.77 - $84.85 $1.2 Million - $3.41 Million
40,199 New
40,199 $2.54 Million
Q4 2020

Feb 04, 2021

SELL
$25.66 - $34.55 $107,977 - $145,386
-4,208 Closed
0 $0
Q3 2020

Nov 09, 2020

SELL
$22.51 - $30.11 $72,819 - $97,405
-3,235 Reduced 43.46%
4,208 $115,000
Q2 2020

Jul 20, 2020

BUY
$12.65 - $29.57 $94,153 - $220,089
7,443 New
7,443 $201,000
Q3 2019

Nov 04, 2019

SELL
$17.46 - $29.05 $174,600 - $290,500
-10,000 Closed
0 $0
Q2 2019

Jul 29, 2019

BUY
$18.0 - $19.82 $180,000 - $198,200
10,000 New
10,000 $198,000

Others Institutions Holding MORF

About Morphic Holding, Inc.


  • Ticker MORF
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,477,100
  • Market Cap $2.19B
  • Description
  • Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...
More about MORF
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.